• Text Size:
    • Increase size
    • Decrease size
    • Reset size
  • EN   RU

Pro Bono Bio's Themes for a Healthier World: Developing New Products : Commercialisation : Humanitarian

Research and Development

Developing New Products

Pro Bono Bio R&D and Manufacturing new medicines for a healthier world

Welcome to Pro Bono Bio

Pro Bono Bio was launched on 12 September 2011 in Moscow marking the visit of British Prime Minister David Cameron to encourage successful Anglo Russian technology projects and companies.

On 28th January 2014 Flexiseq launched nationally in the UK. Commenting on the launch the Prime Minister David Cameron said “It was great to launch Pro Bono Bio during my trade mission to Moscow in 2011. And it is great that less than three years later this innovative treatment for osteoarthritis sufferers has now arrived in the UK. This demonstrates how UK- Russia collaboration at the cutting edge of R&D can help British businesses to expand into new areas, creating jobs and growth here in the UK."

Pro Bono Bio is an international healthcare company born of such an Anglo Russian partnership, based on healthcare experience in product development, commercialisation and finance in London, international capital and the investment and support of RUSNANO in Moscow.

We are the global leader in nano-physical healthcare products and our vision is to build a new international healthcare company based on innovation in both our product development and our business model. We partner with specialist service providers to bring the best talent to bear on key unmet medical needs. In doing so we expect to create and market several commercially important new therapies and thereby grow a new valuable healthcare company.

Flexiseq Osteoarthritis pain relief


Pro Bono Bio launched its first medicine, FLEXISEQ, for the treatment of pain associated with osteoarthritis on 12 September 2011.

FLEXISEQ is the first of an attractive pipeline of products under development that are due for launch over the next five years. Its key benefits are:

  • Proven pain relief and restoration of joint function
  • Excellent Safety Profile.
  • FLEXISEQ is a convenient topical gel
  • FLEXISEQ has NO known drug interactions and has been used in conjunction with other medications prescribed for the pain of osteoarthritis

Nearly all countries report a 10+% incidence of osteoarthritis (and chronic joint pain) and roughly half of those are diagnosed; many of which are seeking improvements in their long term treatment. FLEXISEQ is now successfully launched in Germany, Austria, Ireland, Turkey, Singapore, Malaysia and the UK.

FLEXISEQ is the subject of several global patents and is a trademark beneficially owned by Pro Bono Bio.



Pro Bono Bio, Humanitarian from the Get Go!

Humanitarian Ethos

You are welcome to explore our site to find out more. We particularly recommend you review our first product FLEXISEQ which features the new Sequessome Technology™.


Pro Bono Bio is a commercial organisation based on innovation and partnership, but it also has a core humanitarian value, with a commitment to ship free product to selected disadvantaged areas of the world matching the sales of products at normal prices elsewhere.

Pro Bono Bio made its first humanitarian donation to poor Hajj pilgrims from West Africa in 2012 via the Commission for Pilgrimage to Holy places of Islam.

Arthritis Research UK

Pro Bono Bio® and LloydsPharmacy announced on 28th January 2014 the successful conclusion of the pioneering 2 month Charity exclusive phase of sales of Flexiseq in the UK for the benefit of Arthritis Research UK. The contribution by products sold through the Arthritis Research UK website and through LloydsPharmacy amounts to over £400,000 for the medical research charity. This is part of our humanitarian mission.


Add us on Facebook
Follow us on Twitter
Check our Weibo Site
See our YouTube Channel